Jeanney Lew, MD
Cardiovascular Disease · Manchester, NHNPI 1124439088
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (37.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 63.8% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $17,773, more than ten times the $210 reported in 2019. Among cardiovascular disease clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $366.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$23K
- Medtronic$9K
- Abbott$3K
- Abiomed$335
- Astellas Pharma US Inc$190
- Pfizer$67
- plus $262 from 9 others
What the payments were for
- Consulting fees$5,00014%
- Speaking & faculty fees$10,62530%
- Grants$13,33337%
- Travel & lodging$2,9418%
- Food & beverage$3,4009%
- Education$6372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $22,935 |
| Medtronic(2 entities) | 15 | $9,143 |
| Abbott | 35 | $3,005 |
| Abiomed | 5 | $335 |
| Astellas Pharma US Inc | 5 | $190 |
| Pfizer | 3 | $67 |
| Biosense Webster, Inc. | 2 | $63 |
| Amgen | 3 | $55 |
| AstraZeneca | 2 | $28 |
| Cardinal Health 200 LLC | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Cardiva Medical, Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Inari Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$17,378
- EMBLEM$2,500
- EMBLEM MRI S-ICD$2,500
- AVEIR$2,112
- Impella$276
- Micra$264
- Ensite Cardiac Mapping System$244
- EnSite Precision Cardiac Mapping System$159
- WATCHMAN FLX$118
How this compares
$35,937 in reported general payments places this provider in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $118,015 |
| XareltoRivaroxaban | 22 | $21,253 |
| Metoprolol Succinate | 88 | $1,496 |
| Mexiletine Hcl | 15 | $1,078 |
| Flecainide Acetate | 25 | $1,017 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $659 |
| Amiodarone Hcl | 44 | $348 |
| ClopidogrelClopidogrel Bisulfate | 20 | $252 |
| Potassium Chloride | 11 | $199 |
| Atorvastatin Calcium | 23 | $132 |
| Furosemide | 43 | $128 |
| Lisinopril | 12 | $116 |
| Metoprolol Tartrate | 20 | $110 |
| Losartan Potassium | 14 | $91 |
| Amlodipine Besylate | 19 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $118,015141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.
Other cardiovascular disease in Manchester
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Jinu JohnManchester$12K
- Michelle OuelletteManchester$7K
- Patrick HickleManchester$5K
- Jeffrey BleakleyManchester$5K
- Tong ZhuManchester$4K
- Alan GarstkaManchester$3K
- Stephen HanlonManchester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.